FDA Inspection
Cardinal Biologicals, Inc.Cardinal Biologicals, Inc. – FDA Inspection, May 9, 2025
Record Details
This FDA Inspection record concerns Cardinal Biologicals, Inc., with an inspection on May 9, 2025, issued by the Kansas City District Office, covering biologics.
View Company Profile
ID · f6014819-a3b3-4cf9-9289-5ff24943e840
Inspection Facts
- Inspection number
- 1269612
- FDA center
- Biologics
- Project area
- Blood and Blood Products
FDA Citations
6- 21 CFR 1271.195(c)Monitoring-microorganisms where appropriate
- 21 CFR 1271.200(b)Procedures inadequate
- 21 CFR 1271.200(e)Documentation of use
- 21 CFR 1271.210(a)Use prior to verification
- 21 CFR 1271.60(b)Identified as quarantined, distinguishable
- 21 CFR 1271.60(c)Shipped but not kept in quarantine
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Cardinal Biologicals, Inc.
3| Date | Classification | Office | Project area |
|---|---|---|---|
| February 6, 2018 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| May 24, 2016 | NAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| March 27, 2013 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
Other documents for Cardinal Biologicals, Inc.
- FDA Inspection 1041210 - 2018-02-06
- FDA Inspection 974514 - 2016-05-24
- FDA Inspection 824267 - 2013-03-27
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.